Flossbach Von Storch’s BeOne Medicines Ltd ONC Stock Holding History

Flossbach Von Storch’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,000	Closed	-$486K	–	121
2022 Q2	$486K	Sell	3,000 -1,500	-33%	-$234K	﹤0.01%	114
2022 Q1	$849K	Sell	4,500 -1,000	-18%	-$213K	﹤0.01%	111
2021 Q4	$1.49M	Buy	5,500 +500	+10%	+$169K	﹤0.01%	108
2021 Q3	$1.81M	Buy	+5,000	New	+$1.63M	0.01%	98

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Flossbach Von Storch's ONC Position: Q3 2022 in Review

Flossbach Von Storch sold out of BeOne Medicines Ltd (ONC) in Q3 2022, closing a stake of 3,000 shares — an estimated $486K sold.

Flossbach Von Storch first reported a position in ONC in Q3 2021 and held it in 4 quarters. The position peaked at $1.81M in Q3 2021. 222 funds tracked by Wall St. Rank hold ONC as of Q3 2022.

Flossbach Von Storch reported no remaining BeOne Medicines Ltd position as of Q3 2022 after selling out during the quarter.
Flossbach Von Storch sold 3,000 BeOne Medicines Ltd shares in Q3 2022, an estimated $486K.
Flossbach Von Storch first reported a position in BeOne Medicines Ltd in Q3 2021 and held it in 4 quarters.
Flossbach Von Storch's BeOne Medicines Ltd position peaked at $1.81M in Q3 2021.
222 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2022.

Based on Flossbach Von Storch's 13F filing for Q3 2022, filed 14 Nov 2022.